Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Clinical Trials in China

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University481 Fudan University478 Second Affiliated Hospital, Zhejiang University, School of Medicine401 Ruijin Hospital289 Peking Union Medical College Hospital279
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials in this register

19187 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Active, closed
Fudan University
Phase 2
20
Shanghai
2024-09-30
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
669
Guangzhou, Yixingcun
2024-09-30
Recruiting
Fudan University
Observational
800
Shanghai
2024-09-30
Recruiting
Neoadjuvant Triple Therapy for Resectable HCC
NCT06569498Resectable Hepatocellular Carcinoma
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Fudan University
Phase 2
130
Shanghai
2024-09-30
Recruiting
Yongquan Shi
Phase 2
150
Xi'an
2024-09-30
Recruiting
Fudan University
Phase 2
116
Shanghai
2024-09-30
Recruiting
Zhengzhou University
Phase 4
20
Zhengzhou
2024-09-30
By invitation
Xijing Hospital of Digestive Diseases
Not applicable
44
Xi'an
2024-09-30
Recruiting
Zhejiang Adolescent Spine and Vision Health Cohort: A Longitudinal Database Analysis
NCT06992622Scoliosis Idiopathic, Myopia, Vision Disorders
Second Affiliated Hospital of Wenzhou Medical University
Observational
73,000
Wenzhou
2024-09-30
Active, closed
Pulsed-Field Ablation With/Without Electrogram Mapping
NCT07541989Non-paroxysmal Atrial Fibrillation
Xu Liu
Not applicable
300
Wuhan, Changshu, Xuzhou, Jinan, Wenling, Yuhuan, Shanghai
2024-09-30
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Not yet open
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
40
Nanjing
2024-09-30
Recruiting
Safety and Efficacy of CG-BM1 in Ischemic Stroke
NCT07896941Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
GuangZhou Cellgenes Biotechnology Co., Ltd.
Phase 1/2
87
Guangzhou
2024-09-30
By invitation
Clinical Trial of Anovulatory Infertility
NCT06601452Polycystic Ovary Syndrome, Diminished Ovarian Reserve, Ovulation Disorder
Affiliated Hospital of Nanjing University of Chinese Medicine
Early Phase 1
650
Nanjing
2024-09-30
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
116
Guangzhou
2024-09-30
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hanzhong
2024-09-30
Recruiting
Essen Biotech
Phase 1/2
85
Beijing
2024-09-29
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
380
Tianjin
2024-09-29
Recruiting
Peking University Cancer Hospital & Institute
Phase 1
36
Beijing
2024-09-29
Recruiting
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
NCT05613452Non-small Cell Lung Cancer
Shanghai Proton and Heavy Ion Center
Phase 2
43
Shanghai
2024-09-29
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
By invitation
Peking Union Medical College Hospital
Early Phase 1
40
Beijing
2024-09-28
Recruiting
Xiaoyan Shi
Not applicable
128
Suzhou
2024-09-28
Active, closed
Beijing Tiantan Hospital
Phase 2/3
144
Beijing
2024-09-27
Recruiting
Exploration of Gender Differences in Liver Aging
NCT06591897Healthy Population
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
18
Hangzhou
2024-09-27
Active, closed
Stemline Therapeutics, Inc.
Phase 3
4,556
2024-09-27
Active, closed
Peking University
Not applicable
200
Baoding
2024-09-27
Recruiting
Shanghai Institute Of Biological Products
Phase 2
81
Shanghai
2024-09-27
By invitation
Shanghai Tong Ren Hospital
Not applicable
192
Changning
2024-09-27
Active, closed
Effects of Parent-Adolescent Joint Interventions for Adolescents With Adverse Childhood Experiences
NCT06619821Stress, Emotional, Stress-related Mental Disorders, Adverse Childhood Experiences
Peking University
Not applicable
3,000
Baoding
2024-09-27
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
192
Guangzhou
2024-09-27
Recruiting
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2
30
Beijing
2024-09-27
Not yet open
Meng Qiu
Phase 3
452
Chengdu
2024-09-26
By invitation
Chinese PLA General Hospital
Not applicable
20
Beijing
2024-09-26
Active, closed
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
By invitation
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3
510
Linyi
2024-09-26
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Recruiting
The Feasibility of Pulmonary Perfusion Assessment Using Sodium Bicarbonate Contrast With Electrical Impedance Tomography: A Prospective Pilot Study
NCT07542366Acute Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Pneumonia, Critical Illness
First Affiliated Hospital of Wannan Medical College
Observational
41
Wuhu
2024-09-26
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-09-26
Recruiting
Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC
NCT06623266Oral Cancer, Lymph Node Metastasis
Huashan Hospital
Not applicable
300
Shanghai
2024-09-26
Active, closed
AstraZeneca
Phase 3
293
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang
2024-09-26
Recruiting
Allist Pharmaceuticals, Inc.
Phase 3
380
Guangdong
2024-09-26
Active, closed
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09-26
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Harbin, Shanghai
2024-09-25
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-09-25
Recruiting
Children's Cancer Group, China
Phase 2/3
96
Shanghai
2024-09-25
Recruiting
Magnetoencephalography in Children
NCT06668519Epilepsy, Intracranial Tumors, Cerebrovascular Disease, Autism
Children's Hospital of Fudan University
Observational
1,500
Shanghai
2024-09-25
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
Nanfang Hospital, Southern Medical University
Phase 1
12
Guangzhou
2024-09-25
Active, closed
RJK Biopharma Ltd
Phase 1
9
Beijing
2024-09-24
Not yet open
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
NCT06619886Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1
9
Shanghai
2024-09-24
Recruiting
Tianjin Medical University Second Hospital
Phase 1/2
72
Tianjin
2024-09-24
Recruiting
Chaohui Yu
Early Phase 1
18
Hangzhou
2024-09-24
Recruiting
Ruijin Hospital
Early Phase 1
56
Shanghai
2024-09-24
Recruiting
Ruijin Hospital
Observational
30
Shanghai
2024-09-24
Recruiting
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
NCT06569758Safety, Tolerability, GenSci098, Thyroid Eye Disease (TED)
DrugGenSci098
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
76
Shanghai
2024-09-24
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
5
Xiamen
2024-09-24
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
150
Beijing
2024-09-24
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
39
Guanzhou
2024-09-24
Recruiting
Akeso
Phase 1/2
280
Beijing, Jinan
2024-09-24
Recruiting
Pola-ZR2P in Previously Untreated DLBCL
NCT06664411Diffuse Large B-cell Lymphoma
Navy General Hospital, Beijing
Phase 2
80
Beijing
2024-09-24
Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
60
Guangzhou
2024-09-24
Recruiting
China Medical University Hospital
Phase 2
90
2024-09-23
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）
NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction
Capital Medical University
Phase 3
2,105
Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning
2024-09-23
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Hangzhou
2024-09-23
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
876
Guangzhou
2024-09-23
Recruiting
Functional IOL Implantation in Patients With Epiretinal Membrane
NCT06719739Cataract, Intraocular Lens Complication, Epiretinal Membrane
Eye & ENT Hospital of Fudan University
Not applicable
90
Shanghai
2024-09-21
Active, closed
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
112
Guangzhou
2024-09-21
Recruiting
Combination of TURP and Standard Systemic Therapy for MPCa
NCT06655259Metastatic Prostate Cancer
Fudan University
Phase 2
200
Shanghai
2024-09-21
Recruiting
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244Acute Myeloid Leukemia
Ruijin Hospital
Observational
90
Shanghai
2024-09-21
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Target-specific immunoPET Imaging of Breast Cancer
NCT06715826Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
Drugs[18F]F-RESCA-RB14·[18F]F-RESCA-RT4
RenJi Hospital
Phase 1/2
200
Shanghai
2024-09-21
Recruiting
Peking Union Medical College Hospital
Early Phase 1
10
Beijing
2024-09-20
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
40
Zhenzhou
2024-09-20
Active, closed
EGM Guided PFA for PerAF
NCT06729866Persistent Atrial Fibrillation
Xu Liu
Not applicable
58
Shanghai
2024-09-20
Recruiting
Nanchong Central Hospital
Not applicable
466
Nanchong
2024-09-20
Not yet open
Shanghai Zhongshan Hospital
Phase 2
54
Shanghai
2024-09-20
Recruiting
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Recruiting
Chinese PLA General Hospital
Not applicable
320
Beijing
2024-09-20
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
122
Nanjing, Xuzhou, Yancheng
2024-09-20
Not yet open
Henan University of Traditional Chinese Medicine
Observational
1,016
Zhengzhou
2024-09-20
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Not yet open
Navy General Hospital, Beijing
Phase 2
85
Beijing
2024-09-20
Recruiting
GeneCradle Inc
Phase 1
7
Beijing
2024-09-20
Recruiting
U87 CAR-T in Patients With Advanced Head and Neck Tumors
NCT06614686Nasopharynx Cancer, Head and Neck Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1
20
Shanghai
2024-09-20
Recruiting
Outcomes and Risk Factors of Different Treatment Strategies for Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases
NCT07012668Neuro-co-cardiological Diseases, Post-cardiac Surgery Cerebrovascular Diseases, Vascular Lesion
Beijing Anzhen Hospital
Observational
2,000
Beijing
2024-09-19
By invitation
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
NCT07182175Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)
Peking University First Hospital
Observational
150
Beijing
2024-09-19
Recruiting
Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
NCT06607991CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome, Multidrug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
6
Hangzhou
2024-09-19
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
30
Shanghai
2024-09-19
Recruiting
Dyadic Sport Stacking Program for Mild Dementia and Their Family Caregivers
NCT06597981Dementia, Family Caregivers, Dyadic Intervention, Health Related Quality of Life
The University of Hong Kong
Not applicable
144
Chongqing
2024-09-19
Not yet open
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052Locally Recurrent Rectal Cancer, Preoperative Chemoradiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
100
Guangzhou
2024-09-19
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
423
Beijing
2024-09-19
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Beijing, Chengdu, Shanghai
2024-09-19
Recruiting
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
33
Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
2024-09-19
Active, closed
Wuhan Neurophth Biotechnology Limited Company
Phase 3
95
Beijing
2024-09-19
By invitation
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288Esophageal Cancer, Photodynamic Therapy
Sun Yat-sen University
Phase 4
198
Guangzhou
2024-09-18
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Recruiting
Zhejiang Cancer Hospital
Not applicable
214
Hangzhou
2024-09-18
Active, closed
Analysis of Predictive Factors for Urinary Leakage After Partial Nephrectomy for Renal Hilum Tumors
NCT06916910Partial Nephrectomy, Renal Hilum Tumors, Urinary Leakage
First Affiliated Hospital of Fujian Medical University
Observational
200
Fuzhou
2024-09-18
Recruiting
AstraZeneca
Phase 1/2
174
Hangzhou, Shanghai
2024-09-18
Recruiting
University of Macau
Not applicable
144
2024-09-18
Active, closed
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Active, closed
Dianthus Therapeutics
Phase 2
46
Beijing, Shanghai
2024-09-17
Recruiting
Pierre Fabre Medicament
Phase 1/2
171
Shanghai, Tianjin
2024-09-17
By invitation
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
NCT06504043Hypercholesterolemia, Healthy Volunteers, LDL-Cholesterol
DrugLerodalcibep
Hasten Biopharmaceutical Co., Ltd.
Phase 1
30
Chengdu
2024-09-17
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
By invitation
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Phase 4
414
Zhengzhou
2024-09-16
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
60
Wuhan
2024-09-15
Recruiting
Hui Xu
Phase 4
373
Wuhan
2024-09-15
Active, closed
Evaluation on Visual Outcome of TMS
NCT06612190Visual Impairment
Evidence Based Cataract Study Group
Not applicable
300
Shanghai
2024-09-15
Not yet open
Factors Affecting Selection of Leadless Pacemaker and Atrioventricular Synchronous Pacing Status
NCT06587672Pacemaker, Atrioventricular Block, Clinical Trials, Pacing
Xiaohan Fan
Observational
112
Beijing
2024-09-15
Not yet open
Hunan Province Tumor Hospital
Phase 2
39
Changsha
2024-09-15
Recruiting
A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty
NCT06510764Precocious Puberty, Treatment, Alternative Medicine, Acupuncture
Children's Hospital of Fudan University
Phase 3
170
Shanghai
2024-09-15
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Luye Pharma Group Ltd.
Phase 3
180
Jilin City
2024-09-14
Recruiting
Distribution of Mood and Personality Characteristics and Their Influence on Treatment Compliance
NCT07101796Personality, Patient Compliance, Anxiety, Depression
Peking University First Hospital
Observational
200
Beijing
2024-09-14
Recruiting
Fudan University
Phase 2
76
Shanghai
2024-09-14
Recruiting
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT06548607SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
DrugCD19
Nanjing Bioheng Biotech Co., Ltd.
Early Phase 1
20
Bengbu
2024-09-14
Recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2
60
Shanghai
2024-09-14
Recruiting
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Not applicable
858
Xi'an
2024-09-13
Recruiting
Peking University
Phase 2
34
Beijing
2024-09-13
Recruiting
Hebei Medical University Fourth Hospital
Observational
420
Shijiazhuang
2024-09-13
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Recruiting
FeNO Detection in Asthma Diagnosis: A New Technology Approach
NCT06852911Bronchial Asthma, Airway Disease
Novlead Inc.
Not applicable
170
Shanghai, Wuxi
2024-09-12
By invitation
Cutia Therapeutics（Wuxi）Co.,Ltd
Phase 1
64
Shanghai
2024-09-12
By invitation
Eye & ENT Hospital of Fudan University
Observational
60
Shanghai
2024-09-12
Recruiting
Peking University
Not applicable
80
Beijing
2024-09-12
Recruiting
Qilu Hospital of Shandong University
Phase 1/2
24
Jinan
2024-09-12
Recruiting
Shanghai Chest Hospital
Phase 3
478
Shanghai
2024-09-12
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Beijing, Harbin, Shanghai
2024-09-12
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
99
Hefei, Fuzhou, Quanzhou, Xiamen, Zhangzhou, Shanghai, Hangzhou
2024-09-11
Active, closed
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Observational
130
Yiwu
2024-09-11
Recruiting
Heronova Pharmaceuticals
Phase 1/2
60
Bengbu, Changsha
2024-09-11
Recruiting
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Recruiting
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
NCT06596915Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Breast Cancer, Melanoma
Shandong Boan Biotechnology Co., Ltd
Phase 1
167
Beijing
2024-09-11
Recruiting
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-09-11
Active, closed
Jichao Qin
Observational
1,200
Hangzhou
2024-09-11
Recruiting
Beijing Tiantan Hospital
Early Phase 1
6
Beijing
2024-09-11
Recruiting
Adebrelimab and Chidamide for Pancreatic Cancer
NCT06584227Pancreatic Cancer, Adult
Liu Xiufeng
Phase 2
45
Nanjing
2024-09-10
Active, closed
Fudan University
Phase 2
50
Shanghai
2024-09-10
Recruiting
Statin Combined with Amlodipine Treats Primary Aldosteronism
NCT06523465Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist, Hypertension
DrugsAmlodipine besylate·Simvastatin
Third Military Medical University
Phase 4
180
Chongqing
2024-09-10
Recruiting
Postoperative Complications Following Skull Base Tumor Resection
NCT06587906Skull Base Tumor, Postoperative Complications
Beijing Tiantan Hospital
Observational
122
Beijing
2024-09-10
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma, Esophageal Cancer
DrugsCyclophosphamid·Tumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine
Essen Biotech
Phase 1/2
75
Beijing
2024-09-10
Recruiting
Eighth Affiliated Hospital, Sun Yat-sen University
Phase 3
477
Guangzhou, Puning, Shenzhen, Xiangyang
2024-09-10
Recruiting
Shandong Cancer Hospital and Institute
Observational
4,000
Jinan
2024-09-10
Active, closed
Women's Hospital School Of Medicine Zhejiang University
Observational
200
Hangzhou
2024-09-10
Recruiting
The First Affiliated Hospital of Soochow University
Observational
50
Suzhou
2024-09-10
Not yet open
Ming-an Yu
Observational
300
Beijing
2024-09-10
Recruiting
China-Japan Friendship Hospital
Not applicable
216
Beijing
2024-09-10
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
150
Beijing
2024-09-10
Recruiting
Zhujiang Hospital
Not applicable
126
Guangzhou
2024-09-10
Recruiting
Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment
NCT06348420Gastroesophageal Reflux Disease
Qilu Hospital of Shandong University
Not applicable
74
Jinan
2024-09-10
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3
420
Beijing, Shanghai
2024-09-10
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Active, closed
Pierre Fabre Medicament
Observational
368
Tianjin
2024-09-10
Recruiting
Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China
NCT07113808Abdominal Neoplasm, Abdominal Injury, Ascites
DrugSonoVue
The Children's Hospital of Zhejiang University School of Medicine
Observational
108
Hangzhou
2024-09-10
Recruiting
Fujian Cancer Hospital
Observational
200
Fuzhou
2024-09-07
Recruiting
Eye & ENT Hospital of Fudan University
Not applicable
100
Shanghai
2024-09-07
Recruiting
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
NCT06577519Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
DrugClopidogrel
Jiangsu vcare pharmaceutical technology co., LTD
Phase 3
1,000
Shenyang
2024-09-06
Recruiting
Pinoxin for the Prevention of Radiation-Induced Skin Injury
NCT07545720Cancer Patients Undergoning Radiotherapy
Fudan University
Phase 2
202
Shanghai
2024-09-05
Recruiting
ICAS Screen Based on RIC
NCT06610578Intracranial Atherosclerosis
Xuanwu Hospital, Beijing
Observational
2,100
Beijing
2024-09-05
Active, closed
Zhou Chengzhi
Observational
100,000
Guangdong
2024-09-05
Recruiting
Fudan University
Observational
600
Shanghai
2024-09-05
Recruiting
Peking Union Medical College Hospital
Phase 2
124
Beijing
2024-09-05
Recruiting
The First Affiliated Hospital of Nanchang University
Early Phase 1
12
Nanchang
2024-09-05
Active, closed
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Active, closed
Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding
NCT06031402Acute Upper Gastrointestinal Bleeding, Acute Variceal Bleeding
General Hospital of Shenyang Military Region
Not applicable
368
Shenyang
2024-09-04
Recruiting
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1
10
Suzhou
2024-09-04
Active, closed
Li-kun Chen
Phase 2
70
Guangzhou
2024-09-04
Recruiting
The EEG Study Under Sevoflurane Anesthesia in Children
NCT06580028Electroencephalography, Sevoflurane, Child Neglect
Second Affiliated Hospital of Wenzhou Medical University
Observational
280
Wenzhou
2024-09-04
Recruiting
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Beijing Chao Yang Hospital
Not applicable
60
Beijing
2024-09-04
Recruiting
Tcelltech Inc.
Phase 1
52
Beijing
2024-09-04
Recruiting
AbbVie
Phase 2
590
2024-09-04
Active, closed
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xi’an
2024-09-03
Active, closed
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
304
Nanjing
2024-09-03
Recruiting
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Recruiting
Hangzhou Valgen Medtech Co., Ltd
Not applicable
236
Chengdu, Hangzhou
2024-09-03
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
130
Shanghai
2024-09-03
Recruiting
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
NCT06289751Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
DrugsPaclitaxel-albumin·Cadonilimab·Cisplatin
Tongji Hospital
Phase 2
50
Wuhan, Jinan
2024-09-03
Recruiting
The Affiliated Hospital of Putian University
Phase 2
42
Putian
2024-09-03
Recruiting
Sun Yat-sen University
Phase 1
16
Guangzhou
2024-09-03
Recruiting
A RWS of SC MTX in Chinese RA Patients
NCT07463937Rheumatoid Arthritis (RA)
Peking University People's Hospital
Observational
10,000
Beijing
2024-09-03
Recruiting
Xu Yong, MD
Phase 2
30
Shenzhen
2024-09-03
By invitation
Screening and Prospective Cohort Study of Risk Factors for Enhanced Recovery After Spinal Fusion Surgery in Advanced Age Patient
NCT06591442Lumbar Disk Herniation, Lumbar Spinal Stenosis, Lumbar Spondylolisthesis, Cervical Spondylotic Myelopathy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
500
Wuhan
2024-09-03
Recruiting
Ruijin Hospital
Observational
300
Shanghai
2024-09-02
Recruiting
Jiangsu Nutai Biologics Co., Ltd
Early Phase 1
28
Beijing
2024-09-02
Recruiting
Changhai Hospital
Not applicable
194
Shanghai
2024-09-02
Recruiting
CS-206 in Patients With Sickle Cell Disease
NCT06565026Sickle Cell Disease
CorrectSequence Therapeutics Co., Ltd
Early Phase 1
5
Nanning
2024-09-02
Recruiting
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
NCT06549855Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
DrugSintilimab
Peking University People's Hospital
Not applicable
10
Beijing
2024-09-02
Recruiting
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
NCT06215989Acute Coronary Syndrome, Unstable Angina, ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction
DrugsColchicine Pill·Colchicine
Beijing Anzhen Hospital
Not applicable
6,574
Beijing
2024-09-02
Recruiting
First Affiliated Hospital of Wenzhou Medical University
Observational
216
Wenzhou
2024-09-02
Active, closed
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1/2
39
Shanghai
2024-09-02
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
265
Shanghai
2024-09-02
Not yet open
Shanghai Chest Hospital
Not applicable
134
Wuhan, Nanchang, Shanghai, Ürümqi, Wenzhou
2024-09-01
Active, closed
Nanfang Hospital, Southern Medical University
Observational
17
Guangzhou
2024-09-01
Recruiting
Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring
NCT06604156Depth of Anesthesia, Nociception, Painless Gastrointestinal Endoscopy
Min Su
Observational
220
Chongqing
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD
NCT06914466Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Sleep Disorder
Xuanwu Hospital, Beijing
Observational
20
Beijing
2024-09-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
300
Zhengzhou
2024-09-01
Recruiting
Peking University First Hospital
Observational
340
Beijing
2024-09-01
Recruiting
OSAHS Screening in Diverse Populations
NCT07736872Obstructive Sleep Apnea (OSA), Snoring, Prevalence, Questionnaires and Surveys
Kang Wu
Observational
100,000
Guangzhou, Anshun
2024-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2024-09-01
Recruiting
Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
NCT06108414Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events
DrugRivaroxaban
China National Center for Cardiovascular Diseases
Phase 4
4,374
Beijing
2024-09-01
Recruiting
Changhai Hospital
Not applicable
20
Shanghai
2024-09-01
Recruiting
Peking University People's Hospital
Observational
3,000
Beijing
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Association Between Blood Pressure and Risk of PSCI
NCT06730711Stroke, Cognitive Decline, Blood Pressure
First Affiliated Hospital of Chongqing Medical University
Observational
600
Chongqing
2024-09-01
Recruiting
Zhou Chengzhi
Phase 1/2
20
Guangzhou
2024-09-01
Recruiting
Yunnan Cancer Hospital
Observational
40
Kunming
2024-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Recruiting
Children's Hospital of Fudan University
Not applicable
150
Shanghai
2024-09-01
Active, closed
Diet Intervention on Obesity Related Complication
NCT06719466Obese, Stomach Diseases
Zhang Manna
Not applicable
30
Shanghai
2024-09-01
Recruiting
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
NCT06572319HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
DrugDisitamab Vedotin
Zhejiang Cancer Hospital
Phase 1/2
35
Hangzhou
2024-09-01
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Chinese PLA General Hospital
Phase 2
30
Beijing
2024-09-01
By invitation
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
30
Beijing
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Peking Union Medical College Hospital
Phase 2
40
Beijing
2024-09-01
Not yet open
Nanjing University
Phase 4
300
Nanjing
2024-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2024-09-01
Not yet open
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
NCT06559644Leukemia, Myeloid, Acute, B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Early Phase 1
20
Suzhou
2024-09-01
By invitation
Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease
NCT06641843Kawasaki Disease, Cardiovascular Disease, Anomalous Origin of Coronary Artery
West China Second University Hospital
Observational
240
Chengdu
2024-09-01
Recruiting
Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy
NCT07551037Acute Myeloid Leukemia, Personalized Active Immunotherapy, Maintenance Therapy
Fujian Medical University Union Hospital
Phase 1
90
Fuzhou
2024-09-01
Not yet open
Fudan University
Phase 2
30
Shanghai
2024-09-01
By invitation
West China Second University Hospital
Observational
800
Chengdu
2024-09-01
Recruiting
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
NCT06676527Neoplasms, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms
Jinling Hospital, China
Observational
39
Nanjing
2024-09-01
Recruiting
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Active, closed
Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study
NCT06330233Diabetic Peripheral Neuropathy, Pain, Moxibustion, Randomized Controlled Trial
Zhejiang Chinese Medical University
Not applicable
90
Hangzhou
2024-09-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
50
Xiamen
2024-09-01
Recruiting
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
NCT05188859Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
DrugsAnlotinib·Sintilimab·Pemetrexed·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
29
Taiyuan, Beijing
2024-09-01
Active, closed
Qianfoshan Hospital
Observational
1,200
Jinan
2024-09-01
Recruiting
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
228
Yiwu
2024-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
152
Hangzhou
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
NCT07019233Real Time Pressure Controller, Breast Cancer, Albumin Paclitaxel, Peripheral Neuropathy
Tianjin Medical University Cancer Institute and Hospital
Not applicable
118
Tianjin
2024-09-01
Active, closed
Zhejiang Cancer Hospital
Observational
100
Zhejiang
2024-09-01
By invitation
Anhui Medical University
Observational
600
Hefei
2024-09-01
Not yet open
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2
43
Guangzhou
2024-09-01
Recruiting
Guangzhou Medical University
Observational
1,000
Guangzhou
2024-09-01
Recruiting
RenJi Hospital
Not applicable
104
Shanghai
2024-09-01
Not yet open
Chinese PLA General Hospital
Phase 2
100
Beijing
2024-09-01
Active, closed
Peking University People's Hospital
Observational
70
Beijing
2024-09-01
Not yet open
The First Affiliated Hospital of Zhejiang Chinese Medical University
Not applicable
2,000
Hangzhou
2024-09-01
Not yet open
Beijing Municipal Administration of Hospitals
Not applicable
52
Beijing
2024-09-01
Recruiting
AI App for Management of Atopic Dermatitis
NCT06362629Atopic Dermatitis, Artificial Intelligence
West China Hospital
Not applicable
232
Chengdu
2024-09-01
Active, closed
Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer
NCT06614660Colorectal Cancer, Imaging, Metabolomics, Prognosis
First Affiliated Hospital of Chongqing Medical University
Observational
800
Chongqing
2024-09-01
Recruiting
Mingzhi Zhang
Phase 1/2
50
Zhengzhou
2024-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2024-09-01
Active, closed
Zhimin Shao
Phase 3
307
Shanghai
2024-09-01
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
By invitation
The Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) Targeting the Right Globus Pallidus Internus (GPi) for Motor Symptoms in Patients With PD
NCT06931483Temporal Interference Stimulation, Parkinson's Disease, the Right Globus Pallidus Internus, Motor Symptoms
Yanghua Tian
Not applicable
40
Hefei
2024-09-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
302
Guanzhou
2024-09-01
Recruiting
Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes
NCT04532346Interstitial Lung Disease, Surfactant Dysfunction
DrugHydroxychloroquine
Children's Hospital of Fudan University
Early Phase 1
60
Shanghai
2024-09-01
Recruiting
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
NCT06739265Peripheral T-cell Lymphoma
DrugsCHOP·Golidocitinib
Peking Union Medical College Hospital
Phase 1/2
68
Beijing
2024-09-01
Active, closed
The Second Affiliated Hospital of Chongqing Medical University
Observational
624
Chongqing
2024-09-01
Recruiting
Ever Supreme Bio Technology Co., Ltd.
Phase 1/2
60
2024-09-01
By invitation
Nanfang Hospital, Southern Medical University
Observational
1,500
Guangzhou
2024-09-01
Recruiting
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
NCT06642025Acute Myeloid Leukemia (AML), CAR-T
Zhimin Zhai
Early Phase 1
9
Hefei
2024-09-01
Recruiting
Xuanwu Hospital, Beijing
Not applicable
30
Beijing
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Active, closed
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
250
Chongqing
2024-09-01
Recruiting
Doppler Ultrasound-Guided Angiopuncture for Dysmenorrhea Pain: A Clinical Trial
NCT07176910Angiopuncture, Dysmenorrhea, Dopplar Ultrasound
City University of Hong Kong
Not applicable
30
Changchun
2024-09-01
Active, closed
MRI Assessment of Pancreatic Fat Changes and Islet Function Recovery After Bariatric Surgery in Obese Patients
NCT07464223Obesity & Overweight, Type 2 Diabetes Mellitus (T2DM), Pancreatic Steatosis, Insulin Resistance
yu li，MD
Observational
50
Qingdao
2024-09-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
130
Foshan, Guangzhou, Jieyang, Shantou
2024-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2024-09-01
By invitation
Chinese Medical Association
Not applicable
120
Beijing
2024-09-01
Active, closed
Qianfoshan Hospital
Observational
1,200
Jinan
2024-09-01
Recruiting
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
NCT07166445Carcinoma, Renal Cell, Diagnostic Imaging, Pathology, Deep Learning
Peking University First Hospital
Observational
1,000
Beijing
2024-09-01
By invitation
Peking Union Medical College Hospital
Early Phase 1
40
Beijing
2024-09-01
Recruiting
Magnetic Seizure Therapy for Psychotic Disorders
NCT06581302Psychotic Disorders
Shanghai Jiao Tong University School of Medicine
Not applicable
50
Shanghai
2024-09-01
Recruiting
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
NCT06864221Hepatocellular Carcinoma, Radiotherapy, Treatment Outcome, Biomarkers
Nanfang Hospital, Southern Medical University
Observational
260
Guangzhou
2024-09-01
Recruiting
Shanghai Changzheng Hospital
Phase 2
75
Shanghai
2024-09-01
Recruiting
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
NCT06595992Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2024-09-01
Active, closed
The First Affiliated Hospital with Nanjing Medical University
Early Phase 1
48
Nanjing
2024-09-01
Active, closed
Peking Union Medical College Hospital
Not applicable
660
Beijing
2024-09-01
Not yet open
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
76
Nanjing
2024-09
Not yet open
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
NCT06567080B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma
DrugJWCAR201
RenJi Hospital
Phase 1
15
Shanghai
2024-09
Not yet open
Research on the Impact of Chronic Pelvic Pain on Endometriosis
NCT06584760Chronic Pelvic Pain, Endometriosis
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Observational
60
Yiwu
2024-09
Recruiting
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
NCT06523673Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
104
Hangzhou
2024-09
Not yet open
Xuanwu Hospital, Beijing
Not applicable
124
Beijing
2024-09
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-09
Not yet open
Xuanwu Hospital, Beijing
Not applicable
164
Beijing
2024-09
Not yet open
The Second Hospital of Shandong University
Observational
2,000
Jinan
2024-09
Not yet open
Fudan University
Phase 2
242
Shanghai
2024-09
Not yet open
Ruijin Hospital
Phase 2
45
Shanghai
2024-09
Not yet open
Fudan University
Phase 2
94
Shanghai
2024-08-31
Recruiting
iCell Gene Therapeutics
Phase 1
20
Chengdu
2024-08-31
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
43
Hanzhou
2024-08-31
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hanzhou
2024-08-31
Recruiting
Real-World Case Registry Study on Obesity
NCT07448090Obesity & Overweight, Obesity (Disorder)
Hubei Hospital of Traditional Chinese Medicine
Observational
10,000
Wuhan
2024-08-31
Not yet open
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1
21
Beijing
2024-08-31
Not yet open
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
144
Shanghai
2024-08-31
Recruiting
AR Training Versus Patching in Unilateral Amblyopia
NCT06498206Amblyopia Unilateral
Eye & ENT Hospital of Fudan University
Not applicable
114
Shanghai
2024-08-31
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
38
Hanzhou
2024-08-31
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-08-30
Recruiting
West China Hospital
Phase 2
51
Chengdu
2024-08-30
Recruiting
Changzhou No.2 People's Hospital
Early Phase 1
9
Changzhou
2024-08-30
Recruiting
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
20
Beijing
2024-08-30
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Recruiting
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
66
Beijing, Tianjin
2024-08-30
By invitation
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
NCT07833852Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Shanghai Zerun Biotechnology Co.,Ltd
Observational
486
Mianyang
2024-08-30
Active, closed
Guangdong Provincial People's Hospital
Observational
330
Guangzhou
2024-08-30
Recruiting
Beijing Tsinghua Chang Gung Hospital
Observational
140
Beijing
2024-08-30
Active, closed
Xijing Hospital
Not applicable
200
Shanxi
2024-08-30
Recruiting
Children's Hospital of Fudan University
Not applicable
1,600
Shanghai
2024-08-30
Recruiting
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122Metastatic Castration-resistant Prostate Cancer
DrugBlood samples for PK
Full-Life Technologies UK Limited
Phase 1
50
Beijing, Shanghai
2024-08-30
Recruiting
Navy General Hospital, Beijing
Phase 2
240
Beijing
2024-08-30
Recruiting
Kunwei Shen
Observational
150
Shanghai
2024-08-30
Recruiting
Central South University
Not applicable
60
Changsha
2024-08-30
Not yet open
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NCT06500507Relapsed or Refractory Multiple Myeloma
DrugQLS4131
Qilu Pharmaceutical Co., Ltd.
Phase 1
90
Tianjin
2024-08-30
Recruiting
ShangHai Ji Ai Genetics & IVF Institute
Not applicable
208
Shanghai
2024-08-30
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
78
Beijing
2024-08-29
Recruiting
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
NCT06699979Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, Non-Small Cell Lung Cancer
Central South University
Observational
300
Changsha
2024-08-29
Recruiting
The Affiliated Hospital Of Guizhou Medical University
Early Phase 1
40
Guiyang
2024-08-29
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
Junjie Hang
Not applicable
20
Shenzhen
2024-08-28
Active, closed
Rui He
Not applicable
240
Guangzhou
2024-08-28
Recruiting
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Recruiting
BeBetter Med Inc
Phase 2
30
Guangzhou
2024-08-28
Active, closed
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
1,430
Shanghai
2024-08-28
By invitation
Dongliang Zhang, MD
Phase 4
80
Beijing
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315Hepatocellular Carcinoma, Adjuvant Therapy
DrugDonafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
204
Guangzhou
2024-08-28
Active, closed
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Active, closed
Chinese PLA General Hospital
Observational
3,000
Beijing, Hangzhou
2024-08-27
Recruiting
Hua Zhang
Phase 2
36
Jinan
2024-08-27
Active, closed
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Shanghai
2024-08-26
Active, closed
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
116
Hangzhou
2024-08-26
Recruiting
Sun Yat-Sen University Cancer Center
Observational
50
Guangzhou
2024-08-26
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, Ürümqi, Wuhan
2024-08-26
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 4
284
Chongqing
2024-08-26
Recruiting
Huai'an First People's Hospital
Phase 2
51
Huai'an
2024-08-25
Not yet open
Guangdong Provincial People's Hospital
Not applicable
98
Guangzhou
2024-08-25
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Harbin, Shanghai
2024-08-24
Recruiting
Shanghai Mental Health Center
Observational
125
Shanghai
2024-08-24
Recruiting
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
100
Yiwu
2024-08-24
Recruiting
The First Affiliated Hospital of Dalian Medical University
Not applicable
70
Dalian
2024-08-23
Recruiting
Tang Xiaodong
Phase 1/2
45
Beijing
2024-08-23
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
108
Hangzhou
2024-08-23
Active, closed
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
Recruiting
Shengjing Hospital
Phase 2
93
Shenyang
2024-08-23
Recruiting
iRegene Therapeutics Co., Ltd.
Phase 1
6
Wuhan
2024-08-23
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Recruiting
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative
DrugsCyclophosphamid·Tumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine
Essen Biotech
Phase 1/2
85
Beijing
2024-08-22
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974138Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
DrugsAmlodipine besylate and folic acid·Amlodipine besylate·Amlodipine
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
32,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
24,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3
460
Shanghai
2024-08-22
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xi’an, Beijing, Shanghai
2024-08-22
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
536
Beijing
2024-08-22
Active, closed
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
20
Shanghai, Wuhan
2024-08-22
Recruiting
Peking Union Medical College Hospital
Not applicable
348
Beijing
2024-08-21
Recruiting
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Jiazhuang, Jinan, Nanchang
2024-08-21
Active, closed
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
70
Hangzhou
2024-08-21
Recruiting
Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
NCT07399210Lung Cancer (Diagnosis), Fragmentomics
Baohui Han
Observational
240
Shanghai
2024-08-21
Recruiting
Guangdong Provincial People's Hospital
Phase 2
240
Dongguan, Foshan, Guangzhou, Shenzhen, Zhanjiang, Zhuhai, Haikou
2024-08-21
Recruiting
Peking University Third Hospital
Not applicable
300
Beijing
2024-08-21
Active, closed
MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma
NCT06640153Gastric Cancer, Gastroesophageal Junction Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-08-21
Not yet open
Priority-Matching Correction Technique in Degenerative Lumbar Scoliosis
NCT06470165Degenerative Lumbar Disease, Scoliosis, Degenerative Scoliosis
Xuanwu Hospital, Beijing
Not applicable
200
Beijing
2024-08-21
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Not applicable
60
Nanjing
2024-08-21
Active, closed
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
211
Shanghai
2024-08-21
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1
6
Wuhan
2024-08-20
Recruiting
Jinming Zhang
Phase 1
36
Beijing
2024-08-20
Recruiting
Hua Zhu
Not applicable
50
Beijing
2024-08-20
Recruiting
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Phase 3
570
Fuzhou
2024-08-20
Recruiting
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
NCT06891157Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
DrugsR-Chop·Chidamide
The First Affiliated Hospital with Nanjing Medical University
Phase 2
148
Nanjing
2024-08-20
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
122
Guangzhou
2024-08-20
Recruiting
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-08-20
Recruiting
Liu Huang
Not applicable
80
Wuhan
2024-08-20
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Lung Cancer Recurrent
DrugsTumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine·Cyclophosphamide
Essen Biotech
Phase 1/2
85
Beijing
2024-08-20
Recruiting
ADSCs Therapy in Patients With CTD-ILD
NCT06574581Connective Tissue Diseases, Interstitial Lung Disease
China Medical University Hospital
Phase 1/2
16
2024-08-20
Active, closed
AbbVie
Phase 3
699
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
Not yet open
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
80
Shanghai
2024-08-19
Recruiting
Fudan University
Phase 4
60
Shanghai
2024-08-19
Recruiting
Yi Zhang
Early Phase 1
100
Zhengzhou
2024-08-18
By invitation
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
NCT06350331Venous Thromboembolism, Digital Health, Health Education
Navy General Hospital, Beijing
Not applicable
256
Beijing
2024-08-17
Active, closed
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Recruiting
Dai, Guanghai
Phase 2
46
Beijing
2024-08-16
By invitation
Shanghai Chest Hospital
Observational
500
Shanghai
2024-08-16
Recruiting
Shubo Song
Not applicable
10
Zhengzhou
2024-08-16
Recruiting
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
80
Beijing, Fuzhou, Wenzhou, Changsha, Nanjing, Suzhou, Qingdao, Chengdu
2024-08-16
Active, closed
Novel Lenses for Myopia Progression Trial
NCT06563700Myopia, Progressive
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
342
Shanghai
2024-08-16
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
20
Hangzhou
2024-08-15
Recruiting
Anhui Provincial Hospital
Observational
318
Hefei
2024-08-15
By invitation
Evaluating the Safety and Efficacy of Prosthetic Polymer Heart Valves for the Treatment of Aortic Valve Disease
NCT06518681Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Regurgitation
Suzhou Hearthill Medical Technology Co.,LTD
Not applicable
10
Shanghai
2024-08-15
Recruiting
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
NCT06479356Non-Hodgkin Lymphoma, Large B-cell Lymphoma
DrugRelma-cel
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
12
Tianjin
2024-08-15
Recruiting
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
NCT06531486Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
96
Beijing
2024-08-15
Recruiting
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
NCT06561399Hepatocellular Carcinoma Non-resectable
Fujian Provincial Hospital
Observational
28
Fuzhou
2024-08-15
Not yet open
Effect of Aerobic Interval Training on Atrial Fibrillation Burden
NCT06491329Atrial Fibrillation, Cardiac Rehabilitation
Navy General Hospital, Beijing
Not applicable
156
Beijing
2024-08-15
Not yet open
OXiris for Abdominal SEptic Shock (OASES Study)
NCT06504316Septic Shock, Abdominal Sepsis, Multi Organ Failure, Blood Purification
RenJi Hospital
Not applicable
192
Shanghai
2024-08-15
Recruiting
Shanghai 6th People's Hospital
Observational
75
Shanghai
2024-08-15
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-08-15
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
208
Zhengzhou
2024-08-15
By invitation
Beijing Anzhen Hospital
Observational
90
Beijing
2024-08-15
Not yet open
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Early Phase 1
12
Nanjing
2024-08-15
Not yet open
Zhejiang University
Not applicable
200,000
Hangzhou
2024-08-15
Recruiting
Fudan University
Phase 2
36
Shanghai
2024-08-15
Recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Recruiting
RenJi Hospital
Observational
50
Shanghai
2024-08-15
Active, closed
Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study
NCT06461338Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Guangzhou University of Traditional Chinese Medicine
Not applicable
60
Guangzhou, Nanjing
2024-08-15
Recruiting
Dai, Guanghai
Phase 2
35
Beijing
2024-08-15
Active, closed
Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapy
NCT06581653Chronic Pancreatitis, Pancreatic Exocrine Insufficiency
Changhai Hospital
Not applicable
204
Shanghai
2024-08-15
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Shanghai, Changchun, Beijing
2024-08-15
Recruiting
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2/3
574
Harbin, Shenyang
2024-08-15
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
180
Ningbo
2024-08-14
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
Tianjin
2024-08-14
Recruiting
Beijing Chest Hospital, Capital Medical University
Phase 2
35
Beijing
2024-08-14
Active, closed
Chipscreen Biosciences, Ltd.
Phase 2
42
Shanghai
2024-08-13
Recruiting
Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial
NCT06553053Crohn's Disease Relapse, Inflammatory Bowel Diseases
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Not applicable
106
Shanghai
2024-08-13
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
148
Tianjin
2024-08-13
Active, closed
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Active, closed
Bolt CSP-M Holter Study
NCT06540521Heart Failure, Bradycardia
Medtronic Cardiac Rhythm and Heart Failure
Observational
95
Shanghai, Hangzhou
2024-08-13
Recruiting
Peking Union Medical College Hospital
Not applicable
425
Beijing
2024-08-13
Active, closed
Wei Zhou
Phase 2
32
Chongqing
2024-08-13
Recruiting
Chengcheng Guo
Phase 2
40
Guangzhou
2024-08-13
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
100
Guangzhou
2024-08-13
Recruiting
Fudan University
Phase 2
46
Shanghai
2024-08-13
Recruiting
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
NCT06553898Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2024-08-13
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Recruiting
The First Hospital of Jilin University
Phase 1/2
35
Changchun
2024-08-13
Recruiting
Hypofractionated Radiotherapy
NCT06740955Glioblastoma
The First Hospital of Jilin University
Not applicable
420
Changchun
2024-08-13
Recruiting
A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects
NCT06599528Assisted Reproductive Technology, Female Infertility
Suzhou Centergene Pharmaceuticals Co.,Ltd.
Phase 1
48
Suzhou
2024-08-12
Recruiting
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Not yet open
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
90
Shanghai
2024-08-12
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
100
Nanjing
2024-08-12
Recruiting
Fudan University
Phase 2
25
Shanghai
2024-08-12
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
Qifu Li
Observational
97
Chongqing
2024-08-12
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
528
Shanghai
2024-08-12
Recruiting
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
NCT06279351Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
DrugsThalidomide·Cetuximab
Xinqiao Hospital of Chongqing
Phase 2
96
Chongqing
2024-08-11
Active, closed
A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT06516068Obstructive Hypertrophic Cardiomyopathy
DrugHRS-1893
Shandong Suncadia Medicine Co., Ltd.
Phase 2
42
Beijing
2024-08-11
Recruiting
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06530550Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
51
Tianjin
2024-08-10
Recruiting
Efficacy and Safety of Rifaximin in Treating MAFLD
NCT07185932Metabolic-associated Fatty Liver Disease
DrugRifaximin
Shanghai Changzheng Hospital
Early Phase 1
40
Shanghai
2024-08-10
Active, closed
Posterior Minimally Invasive Surgery for Treating Paralytic Scoliosis With Pelvic Obliquity in Children Following Spinal Cord Injury
NCT07594574Paralytic Scoliosis, Pelvic Obliquity, Spinal Cord Injury, Neuromuscular Scoliosis
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
39
Nanjing
2024-08-10
Recruiting
Huashan Hospital
Observational
300
Shanghai
2024-08-10
Not yet open
Xuanwu Hospital, Beijing
Not applicable
60
Beijing
2024-08-10
Recruiting
Zhejiang University
Not applicable
5
Hangzhou
2024-08-10
Recruiting
Guangdong Provincial People's Hospital
Phase 4
39
Guangzhou
2024-08-10
Active, closed
Xia Peng
Observational
174
Shanghai
2024-08-10
Recruiting
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
NCT06530576T-LGL Leukemia, NK-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
48
Tianjin
2024-08-10
Recruiting
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
NCT06485466Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
Guohui Xu
Phase 3
101
Chengdu
2024-08-10
Not yet open
RenJi Hospital
Phase 2
80
Shanghai
2024-08-10
Recruiting
Sun Yat-sen University
Not applicable
1,200
Guangzhou
2024-08-10
Recruiting
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
Yunpeng Liu
Not applicable
38
Shenyang
2024-08-09
Active, closed
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 3
350
Shanghai
2024-08-09
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
40
Shanghai
2024-08-09
Recruiting
Peking Union Medical College Hospital
Phase 2
27
Beijing
2024-08-09
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
118
Shanghai
2024-08-09
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Phase 1/2
10
Hangzhou
2024-08-09
Recruiting
Oneness Biotech Co., Ltd.
Phase 2
114
2024-08-08
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
22
Nanjing
2024-08-08
Recruiting
SciClone Pharmaceuticals
Observational
450
Suzhou
2024-08-08
Recruiting
IASO-782 in Autoimmune Hematological Diseases
NCT06534021Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
DrugIASO-782
Shanghai IASO Biotechnology Co., Ltd
Phase 1
16
Wuhan, Tianjin
2024-08-08
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
35
Hangzhou
2024-08-08
By invitation
Zhongnan Hospital
Phase 1/2
25
Wuhan
2024-08-08
Recruiting
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)
NCT06474507Ischemic Cerebrovascular Disease, Acute Ischemic Stroke, Cerebral Small Vessel Diseases
DrugCalculus bovis sativus
Tongji Hospital
Not applicable
230
Wuhan
2024-08-08
Recruiting
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
NCT06311981Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
Jian Chen
Phase 2
29
Shanghai
2024-08-08
Recruiting
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
NCT06474520Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
DrugCalculus bovis sativus
Tongji Hospital
Not applicable
250
Wuhan
2024-08-08
Recruiting
Shenzhen Pulsecare Medical Technology Co., Ltd.
Not applicable
6
Guangzhou
2024-08-08
Active, closed
AbbVie
Phase 3
111
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
Huashan Hospital
Not applicable
830
Shanghai
2024-08-08
Recruiting
Peking Union Medical College Hospital
Phase 2
25
Beijing
2024-08-07
Recruiting
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Active, closed
Effectiveness of a Smart Community- and Home-based Integrated Care Services System for Elderly People
NCT06848036Smart Community- and Home-based Integrated Care Services
Liu Zhihan
Not applicable
64
Changsha
2024-08-07
Active, closed
Fudan University
Phase 2
40
Shanghai
2024-08-07
Recruiting
BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
NCT06598722Lymphoblastic Lymphoma, Adult, Lymphoblastic Leukemia, Acute T-cell
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
206
Shanghai
2024-08-07
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
138
Chengdu
2024-08-07
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
722
Guangzhou
2024-08-07
Recruiting
Ningbo Medical Center Lihuili Hospital
Not applicable
30
Ningbo
2024-08-07
Active, closed
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 2
120
Guangzhou
2024-08-07
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
DrugsJAB-3312·Glecirasib·Pemetrexed·Tislelizumab
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Recruiting
A Study of Online Follow-up in Patients With Papillary Thyroid Cancer
NCT06800482Thyroid, Papillary Thyroid Cancer
West China Hospital
Not applicable
388
Chengdu
2024-08-07
Recruiting
Changhai Hospital
Phase 3
770
Shanghai
2024-08-06
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Active, closed
RenJi Hospital
Not applicable
12
Shanghai
2024-08-06
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
40
Nanjing
2024-08-06
Recruiting
Peking Union Medical College Hospital
Not applicable
40
Beijing
2024-08-06
By invitation
Guangdong Provincial People's Hospital
Not applicable
60
Guangzhou
2024-08-06
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Active, closed
Peking University
Not applicable
1,881
Haidian
2024-08-06
Active, closed
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Recruiting
Beijing GoBroad Hospital
Phase 2
113
Beijing
2024-08-05
Rows per page Showing 12001–12500 of 19187
Previous 23 24 25 26 27 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china?page=25

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,790 of the 19,187 studies in this register are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 3,998 have not yet opened recruitment, 2,715 are active but closed to new participants, and 684 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (423) Advanced Solid Tumors (187) Colorectal Cancer (179) Gastric Cancer (175) Hepatocellular Carcinoma (154) Advanced Solid Tumor (153) Non-Small Cell Lung Cancer (145) Solid Tumor (142) Acute Ischemic Stroke (140) Lung Cancer (135) Non-small Cell Lung Cancer (132) Pancreatic Cancer (131) Multiple Myeloma (128) Coronary Artery Disease (122) Prostate Cancer (110)
→

Browse trials by site location

Beijing (5576) Shanghai (3879) Guangzhou (3345) Hangzhou (1819) Wuhan (1343) Chengdu (1307) Nanjing (1211) Changsha (1154) Chongqing (1078) Fuzhou (1040) Tianjin (934) Zhengzhou (931) Hefei (896) Jinan (783) Changchun (639)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.